Annexon Biosciences GAAP EPS of -$0.25 (ANNX:NASDAQ)

Annexon Biosciences (ANNX) reported a Q3 GAAP EPS of -$0.25. The company has $213 million in cash and short-term investments, expected to last into 2028. Annexon also discussed its vonaprument Phase III ARCHER II trial and plans for a Q4 BLA filing for tanruprubart.

Original reporting
Published Nov 9, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANNX
Bearish
medium confidence
Mentioned
$ANNX
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ANNXBearishMed
01

Why it matters

The loss and cash balance suggest near‑term financial pressure, but the extended runway may support ongoing R&D.

02

Market read

Earnings miss for a micro‑cap biotech, likely prompting short‑term price decline.

03

What to watch

Potential upcoming Phase III data and partnership announcements could offset short‑term earnings disappointment.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Annexon Biosciences is a NASDAQ‑listed biotech focused on ocular disease therapies. The Q3 release includes trial updates and cash position.

Company-level read

Ticker impact

$ANNXBearishMedium confidence
Context

Annexon Biosciences reported Q3 2026 GAAP EPS of -$0.25 and cash of $213 million, indicating a loss and runway into 2028.

Expected impact

likely downward pressure as investors price in the loss and modest cash position

Evidence & confidence

The negative EPS and lack of revenue guidance suggest weaker performance than expectations, which typically triggers sell pressure in micro‑cap biotech stocks.

Market effects

Biotech sector may see slight pullback as earnings miss adds to sector risk sentiment.

US biotech micro‑caps could face broader weakness in after‑hours trading.

Limited; impact confined to niche biotech investors.

Counterpoint

If the cash runway to 2028 is viewed as sufficient for upcoming trial milestones, the stock could be undervalued despite the loss.

Key entities

  • Annexon Biosciences

    NASDAQ‑listed biotech (ticker ANNX) reporting Q3 earnings.

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.